These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16021569)

  • 1. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
    Park K; Kwak K; Kim J; Lim S; Han S
    Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
    Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
    Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
    Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
    Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
    Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
    Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
    Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
    Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.